LitAlert ~~ GeneLit.com

    • Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
    • Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.
    • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    • Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
    • Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.
    • Review